Arabinoxylan (Medium viscosity) 

Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome^[1][2][3].

The viscosity of Arabinoxylan solution increases significantly with rising concentration, exhibiting shear-thinning behavior; viscous behavior dominates at low viscosity, while molecular chains undergo hyperentanglement at high viscosity, leading to a transition from viscoelasticity to elasticity. Additionally, the solution follows the Cox-Merz rule and has no complex long-range structure^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Arabinoxylan Medium viscosity (accounting for 7.8% of dry matter; p.o.; single dose) reduces the net portal glucose absorption in portal vein-cannulated pigs at 60 min and decreases their insulin secretion level at 30 min^[3].
Arabinoxylan Medium viscosity (accounting for 7.1% of dry matter; administered orally; daily dosing; for 7 consecutive weeks) improves glucose homeostasis, as evidenced by reduced levels of fasting blood glucose, OGTT response, insulin, and HbA_1c, while also delaying the onset of diabetes in Zucker diabetic fatty rats^[3].
Arabinoxylan Medium viscosity (accounting for 10% of dry matter; p.o.; daily; for 3 consecutive weeks) does not alter glucose homeostasis or incretin hormone levels in normoglycemic pigs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

9040-27-1

Solid

White to off-white

[Arabinoxylan (Medium viscosity)]

Room temperature in continental US; may vary elsewhere.

Store at room temperature 3 years

• [1]. Sahasrabudhe NM, et al. Arabinoxylan activates Dectin-1 and modulates particulate β-glucan-induced Dectin-1 activation. Mol Nutr Food Res. 2016;60(2):458-467.  [Content Brief]

  [2]. Shelat K J, et al. Diffusion and viscosity in arabinoxylan solutions: Implications for nutrition[J]. Carbohydrate Polymers, 2010, 82(1): 46-53.

  [3]. Knudsen KEB, et al. Arabinoxylan Concentrate from Wheat as a Functional Food Ingredient to Improve Glucose Homeostasis. Nutrients. 2025;17(9):1561. Published 2025 Apr 30.